Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ced/llad164 | DOI Listing |
Publication Analysis
Top Keywords
pembrolizumab-associated expansion
4
expansion radiation-induced
4
radiation-induced morphoea
4
morphoea responsive
4
responsive dupilumab
4
dupilumab case
4
case report
4
pembrolizumab-associated
1
radiation-induced
1
morphoea
1
Similar Publications
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals.
Nat Commun
March 2025
Caris Life Sciences, 4610 S 44th Pl, Phoenix, AZ, 85040, USA.
The US Food and Drug Administration approves tissue-agnostic therapies to target tumor biomarkers regardless of tumor type. In light of the growing number of such approvals in recent years, a better understanding of their relative clinical benefit across cancer types is required. To address this need, we analyzed tissue-agnostic indications (TMB-High, MSI-High/MMRd, BRAF mutations, and NTRK and RET fusions) in a database of 295,316 molecularly-profiled tumor samples with associated clinical outcomes data.
View Article and Find Full Text PDFPembrolizumab-associated expansion of radiation-induced morphoea responsive to dupilumab: a case report.
Clin Exp Dermatol
August 2023
Departments of Dermatology.